Compare Bristol-Myers Squibb Co (BMY) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Ford Motor Company — how do they compare? Bristol-Myers Squibb Co trades at $57.7 (market cap $116.30B), while Ford Motor Company trades at $14.04 (market cap $55.55B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.1× Ford Motor Company's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | F | |
|---|---|---|
Market Cap | $116.30B | $55.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $17.44 |
52-Week Low | $42.60 | $10.82 |
Enterprise Value | $152.24B | $184.57B |
Dividend Yield | 4.42% | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Ford (F) trades at $13.87, down 0.9% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with profitability metrics negative. Recent developments include a labor deal with Unifor, J.D. Power quality recognition, and plans for a $30,000 EV truck in 2027. Analyst consensus is mixed with 35% buy ratings and a $15.00 price target.
Ford faces execution risks in EV transition amid competitive pressures, though valuation appears reasonable with P/E of 11.84 and P/S of 0.29. The stock offers value potential if management can stabilize profitability, but investors should monitor EV execution and margin recovery given current negative ROE of -14.87% and ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
